Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET-01 in Transfusion Dependent β-Thalassemia
NCT04390971Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2023
- Primary completion
- Mar 2023
- Modality
- CRISPR-Cas9, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ET-01 in beta thalassemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Frequency and severity of Adverse Events and Serious Adverse Events at 104 weeks, All-cause mortality at 104 weeks and 2 more. Started Feb 2023; status: completed.
02
Drugs
ET-01
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT04390971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04390971.